<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288169/" ref="ordinalpos=4299&amp;ncbi_uid=4756776&amp;link_uid=PMC3288169" image-link="/pmc/articles/PMC3288169/figure/F4/" class="imagepopup">Figure 4.  From: LBH-589 (Panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism. </a></div><br /><div class="p4l_captionBody">Overexpression of XIAP prevents JNK activation and cell death mediated by the LBH-589/fludarabine regimen, whereas interruption of the JNK signaling pathway fails to reverse XIAP down-regulation.</div></div>